Inventor · disambiguated record
Jason Park
Also filed as: PARK JASON · PARK JASON Y
20 granted patents·25 pending applications·331 citations·filing 2001–2023
95Inventor score
Files withUNIV JEFFERSON12FLAGSHIP PIONEERING INNOVATIONS VI LLC7FLAGSHIP PIONEERING INNOVATIONS V INC5UNIV PENNSYLVANIA5UNIV TEXAS5
Top patents by PatentIndex Score
45 records- 0198US7479376B2Compositions and methods for identifying and targeting cancer cells of alimentary canal originUNIV JEFFERSON·Filed 2005·Granted Jan 20, 2009·103 cites·32 claims
- 0298US6767704B2Methods of screening and diagnosing esophageal cancer by determining guanylin cyclase C expressionUNIV JEFFERSON·Filed 2001·Granted Jul 27, 2004·132 cites·30 claims
- 0394US10603276B2Nanolipogel vehicles for controlled delivery of different pharmaceutical agentsUNIV YALE·Filed 2018·Granted Mar 31, 2020·6 cites·20 claims
- 0493US7785817B2Compositions and methods for identifying and targeting cancer cells of alimentary canal originUNIV JEFFERSON·Filed 2008·Granted Aug 31, 2010·7 cites·23 claims
- 0592US8067007B2Compositions and methods for identifying and targeting cancer cells of alimentary canal originWALDMAN SCOTT A·Filed 2010·Granted Nov 29, 2011·6 cites·10 claims
- 0690US11173119B2Nanolipogel vehicles for controlled delivery of different pharmaceutical agentsUNIV YALE·Filed 2019·Granted Nov 16, 2021·2 cites·14 claims
- 0790US8946168B2Compositions and methods for identifying and targeting cancer cells of alimentary canal originWALDMAN SCOTT A·Filed 2011·Granted Feb 3, 2015·4 cites·37 claims
- 0890US7485422B2Detection of CDX2 expressionUNIV JEFFERSON·Filed 2005·Granted Feb 3, 2009·3 cites·27 claims
- 0989US6844153B2Compositions and methods for identifying and targeting cancer cells of alimentary canal originUNIV JEFFERSON·Filed 2001·Granted Jan 18, 2005·13 cites·8 claims
- 1088US9610250B2Nanolipogel vehicles for controlled delivery of different pharmaceutical agentsUNIV YALE·Filed 2013·Granted Apr 4, 2017·8 cites·48 claims
- 1187US7879575B2Nanostructures that provide a modified nanoenvironment for the enhancement of luminescenceUNIV PENNSYLVANIA·Filed 2006·Granted Feb 1, 2011·23 cites·55 claims
- 1285US9429576B2Compositions and methods for identifying and targeting cancer cells of alimentary canal originUNIV JEFFERSON·Filed 2014·Granted Aug 30, 2016·1 cites·18 claims
- 1383US7854933B2Compositions and methods for identifying and targeting cancer cells of alimentary canal originThmoas Jefferson University·Filed 2004·Granted Dec 21, 2010·9 cites·9 claims
- 1480US2010015167A1Compositions and methods for identifying and targeting cancer cells of alimentary canal originUNIV JEFFERSON·Filed 2009·Application pending·0 cites
- 1579US12156939B2Nanolipogel vehicles for controlled delivery of different pharmaceutical agentsUNIV YALE·Filed 2021·Granted Dec 3, 2024·0 cites·13 claims
- 1676US7745114B2Compositions and methods for identifying and targeting cancer cells of alimentary canal originUNIV JEFFERSON·Filed 2003·Granted Jun 29, 2010·2 cites·29 claims
- 1776US2008241064A1Compositions and methods for identifying and targeting cancer cells of alimentary canal originUNIV JEFFERSON·Filed 2008·Application pending·0 cites
- 1873US12498381B2Prediction and treatment of immunotherapeutic toxicityUNIV TEXAS·Filed 2023·Granted Dec 16, 2025·0 cites·21 claims
- 1973US8206704B2Use of GCC ligandsWALDMAN SCOTT A·Filed 2004·Granted Jun 26, 2012·7 cites·26 claims
- 2070US2017049869A1Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal OriginUNIV JEFFERSON·Filed 2016·Application pending·0 cites
- 2165US7919019B2Nanostructure enhanced luminescent devicesUNIV PENNSYLVANIA·Filed 2006·Granted Apr 5, 2011·5 cites·20 claims
- 2265US2011086064A1Compositions and methods for identifying and targeting cancer cells of alimentary canal originUNIV JEFFERSON·Filed 2010·Application pending·0 cites
- 2365US2011250228A1Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal OriginUNIV JEFFERSON·Filed 2010·Application pending·0 cites
- 2464US2004033520A1Compositions and methods for identifying and targeting cancer cells of alimentary canal originFiled 2003·Application pending·0 cites
- 2563US2025197388A1Compounds, pharmaceutical compositions and methods for treating inflammatory bowel diseaseFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2023·Application pending·0 cites
- 2661US11376272B2Methods of modulating immune activityFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2021·Granted Jul 5, 2022·0 cites·30 claims
- 2761US2024150836A1Methods of predicting and treating immunotherapy toxicity based on immune cell populationsUNIV TEXAS·Filed 2023·Application pending·0 cites
- 2860US2022387470A1Methods of modulating immune activityFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2022·Application pending·0 cites
- 2959US11747345B2Prediction and treatment of immunotherapeutic toxicityUNIV TEXAS·Filed 2018·Granted Sep 5, 2023·0 cites·17 claims
- 3053US2024392384A1Diagnosis and treatment of diseases and conditions of the intestinal tractFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2022·Application pending·0 cites
- 3153US2024392374A1Diagnosis and treatment of diseases and conditions of the intestinal tractFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2022·Application pending·0 cites
- 3253US2025122569A1Diagnosis and treatment of diseases and conditions of the intestinal tractFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2022·Application pending·0 cites
- 3353US2023288415A1Prediction and treatment of immunotherapeutic toxicityUNIV TEXAS·Filed 2022·Application pending·0 cites
- 3453US2009246888A1NanoassaysUNIV PENNSYLVANIA·Filed 2006·Application pending·0 cites
- 3553US2025129422A1Diagnosis and treatment of diseases and conditions of the intestinal tractFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2022·Application pending·0 cites
- 3653US2024392375A1Diagnosis and treatment of diseases and conditions of the intestinal tractFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2022·Application pending·0 cites
- 3752US2011124965A1Chemiluminescence enhanced detectionPARK JASON Y·Filed 2009·Application pending·0 cites
- 3852US2012308583A1Use of gcc ligandsWALDMAN SCOTT A·Filed 2012·Application pending·0 cites
- 3952US2011152116A1NanoassaysUNIV PENNSYLVANIA·Filed 2011·Application pending·0 cites
- 4048US2023256033A1Physiologically acceptable compositions containing microorganisms or microbial productsFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2021·Application pending·0 cites
- 4148US2023114107A1Combination anti-cancer therapies with inducers of iron-dependent cellular disassemblyFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2020·Application pending·0 cites
- 4244US2021283091A1Decreasing immune activity through modulation of postcellular signaling factorsFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2019·Application pending·0 cites
- 4343US2007298109A1Nano-scale devicesUNIV PENNSYLVANIA·Filed 2005·Application pending·0 cites
- 4441US2021263045A1Prediction and treatment of immunotherapeutic toxicityUNIV TEXAS·Filed 2019·Application pending·0 cites
- 4537US2021251994A1Increasing immune activity through modulation of postcellular signaling factorsFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jason Park files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →